+

WO1998017237A1 - Compositions a administration orale contenant du gluconate stanneux - Google Patents

Compositions a administration orale contenant du gluconate stanneux Download PDF

Info

Publication number
WO1998017237A1
WO1998017237A1 PCT/US1997/018508 US9718508W WO9817237A1 WO 1998017237 A1 WO1998017237 A1 WO 1998017237A1 US 9718508 W US9718508 W US 9718508W WO 9817237 A1 WO9817237 A1 WO 9817237A1
Authority
WO
WIPO (PCT)
Prior art keywords
sodium
compositions
composition
stannous
gluconate
Prior art date
Application number
PCT/US1997/018508
Other languages
English (en)
Inventor
Robert Ernest Singer, Jr.
Original Assignee
The Procter & Gamble Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Procter & Gamble Company filed Critical The Procter & Gamble Company
Priority to BR9712993-3A priority Critical patent/BR9712993A/pt
Priority to CA002269473A priority patent/CA2269473A1/fr
Priority to EP97911712A priority patent/EP0939612A1/fr
Priority to AU49021/97A priority patent/AU722452B2/en
Publication of WO1998017237A1 publication Critical patent/WO1998017237A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/365—Hydroxycarboxylic acids; Ketocarboxylic acids

Definitions

  • the present invention relates to a method of preventing or controlling colds and similar maladies, such as flu, through the use of an oral composition containing stannous gluconate applied to the gingival or oral mucosal tissue of the subject susceptible to colds.
  • the common cold although not usually a serious illness, is a highly prevalent, discomforting and annoying infliction.
  • the term "common cold” is applied to minor respiratory illnesses caused by a variety of different respiratory viruses. While rhinoviruses are the major known cause of common colds, accounting for approximately 30 percent of colds in adults, viruses in several other groups are also important. While immune responses occur, and infection with some respiratory tract viruses therefore could be prevented by a vaccine, development of a polytypic vaccine to cover all possible agents is impractical. Thus, the problem of controlling acute upper respiratory disease presents complex challenges, and the long-desired discovery of a single cure for the common cold is an unrealistic expectation.
  • compositions for treatment of nasal and other cold, flu, allergy and sinus symptoms and the discomfort, pain, fever and general malaise associated therewith generally contain an analgesic (aspirin or acetaminophen) and one or more antihistamines, decongestants, cough suppressants, antitussives and expectorants.
  • analgesic aspirin or acetaminophen
  • Other specific pharmaceutical actives for nasal symptoms e.g., congestion
  • These actives are generally delivered topically to the nasal mucosa via a nasal spray.
  • oral drugs such as decongestants could pose a risk of unfavorable drug interactions and may cause an adverse reaction. It would, therefore, be highly desirable to deliver relief from specific nasal symptoms via compositions without the need for such pharmaceutical actives.
  • the present invention relates to a method of reducing colds and cold-like symptoms, such as flu, in subjects susceptible to such maladies by applying a composition containing an effective amount of stannous gluconate to the gingival or oral mucosal tissues.
  • compositions of the present invention contain certain essential components as well as non-essential components.
  • Stannous gluconate is an essential component of the present compositions.
  • This material is a known stannous chelate and may be provided to the present compositions as the chelate or as separate soluble stannous and gluconate salts and the chelate formed in-situ.
  • Such salts include stannous chloride and sodium gluconate.
  • Stannous gluconate is present in the present compositions at a level of from about 0.1% to about 11%, preferably from about 0.2% to about 4%.
  • Acceptable Carrier is an essential component of the present compositions.
  • the carrier for the active component(s) can be any vehicle suitable for use in the oral cavity.
  • Such carriers include the usual components of mouthwashes, gargles, toothpastes, tooth powders, prophylaxis pastes, lozenges, gums and the like and are more fully described hereinafter. Dentifrices and mouthwashes are the preferred systems.
  • the present compositions may contain antiplaque/gingivitis agents such as quaternary ammonium compounds, water insoluble agents such as triclosan, teas, as defined herein later, stannous salts and zinc salts.
  • antiplaque/gingivitis agents such as quaternary ammonium compounds, water insoluble agents such as triclosan, teas, as defined herein later, stannous salts and zinc salts.
  • the abrasive polishing material contemplated for use in the present invention can be any material which does not excessively abrade dentin.
  • silicas including gels and precipitates, calcium carbonate, dicalcium orthophosphate dihydrate, calcium pyrophosphate, tricalcium phosphate, calcium polymetaphosphate, insoluble sodium polymetaphosphate, hydrated alumina, and resinous abrasive materials such as particulate condensation products of urea and formaldehyde, and other such as disclosed by Cooley et al. in U.S. Patent 3,070,510, December 25, 1962, incorporated herein by reference. Mixtures of abrasives may also be used.
  • Silica dental abrasives of various types, can provide the unique benefits of exceptional dental cleaning and polishing performance without unduly abrading tooth enamel or dentin.
  • Silica abrasive materials are also exceptionally compatible with sources of soluble fluoride and polyphosphonates. For these reasons they are preferred for use herein.
  • the silica abrasive can be precipitated silica or silica gels such as the silica xerogels described in Pader et al., U.S. Patent No. 3,538,230, issued March 2, 1970 and DiGiulio, U.S. Patent No. 3,862,307, June 21, 1975, both incorporated herein by reference.
  • Preferred precipitated silica materials include those marketed by the J. M. Huber Co ⁇ oration under the tradename, "Zeodent", particularly the silica carrying the designation "Zeodent 119". These silica abrasives are described in U.S. Patent No. 4,340,583, July 29, 1982, inco ⁇ orated herein by reference.
  • the abrasive in the compositions described herein is present at a level of from about 6% to about 70%, preferably from about 15% to about 25% when the dentifrice is a toothpaste. Higher levels, as high as 90%, may be used if the composition is a toothpowder.
  • compositions of the present invention may also contain a soluble fluoride ion source such as sodium, potassium, lithium fluorides, stannous fluoride, and sodium monofluorophosphate among many others.
  • a soluble fluoride ion source such as sodium, potassium, lithium fluorides, stannous fluoride, and sodium monofluorophosphate among many others.
  • the fluoride source should be sufficient to provide from about 50 to about 3500 ppm fluoride in a toothpaste or mouthrinse.
  • Flavoring agents can also be added to dentifrice compositions. Suitable flavoring agents include, among many others, oil of wintergreen, oil of peppermint, oil of spearmint, and oil of clove. Sweetening agents which can be used include aspartame, acesulfame, saccharin, dextrose, levulose and sodium cyclamate. Flavoring and sweetening agents are generally used in dentifrices at levels of from about 0.005% to about 2% by weight.
  • Dentifrice compositions can also contain emulsifying agents. Suitable emulsifying agents are those which are reasonably stable and foam throughout a wide pH range, including nonsoap anionic, nonionic, cationic, zwitterionic and amphoteric organic synthetic detergents. Many of these suitable surfactants are disclosed by Gieske et al. in U.S. Patent No. 4,051,234, September 27, 1977, inco ⁇ orated herein in its entirety by reference.
  • Water is also present in the toothpastes of this invention.
  • Water employed in the preparation of commercially suitable toothpastes should preferably be deionized and free of organic impurities.
  • Water generally comprises from about 10% to 50%, preferably from about 20% to 40%, by weight of the toothpaste compositions herein. These amounts of water include the free water which is added plus that which is introduced with other materials such as with sorbitol.
  • thickening agents are carboxyvinyl polymers of the type mentioned previously herein, xanthan gum, carrageenan, hydroxyethyl cellulose and water soluble salts of cellulose ethers such as sodium carboxymethyl cellulose and sodium carboxymethyl hydroxyethyl cellulose.
  • Natural gums such as gum karaya, gum arabic, and gum tragacanth can also be used.
  • Colloidal magnesium aluminum silicate or finely divided silica can be used as part of the thickening agent to further improve texture.
  • Thickening agents in an amount from 0.5% to 5.0% by weight of the total composition can be used.
  • humectant material in a toothpaste to keep it from hardening.
  • Suitable humectants include glycerin, sorbitol, xylitol, and other edible polyhydric alcohols at a level of from about 5% to about 70%.
  • Mouthwash composition is a mouthwash composition.
  • Conventional mouthwash composition components can comprise the carrier for the active agents of the present invention.
  • Mouthwashes generally comprise from about 20:1 to about 2: 1 of a water/ethyl alcohol solution and preferably other ingredients such as flavor, sweeteners, humectants and sudsing agents such as those mentioned above for dentifrices.
  • the humectants, such as glycerin and sorbitol give a moist feel to the mouth.
  • the mouthwashes of the invention comprise 0% to 60% (preferably 10% to 25%) ethyl alcohol, 0% to 20% (preferably 5% to 20%) of a humectant, 0% to 2% (preferably 0.01% to 0.15%) emulsifying agent, 0% to 0.5% (preferably 0.005% to 0.06%) sweetening agent such as saccharin, 0% to 0.3% (preferably 0.03% to 0.3%) flavoring agent, and the balance water.
  • Suitable lozenge and chewing gum components are disclosed in U.S. Patent No. 4,083,955, April 11, 1978 to Grabenstetter et al., inco ⁇ orated herein by reference.
  • pyrophosphate salts such as those described in U.S. 4,515,772, May 7, 1985 to Parran et al. inco ⁇ orated herein by reference.
  • nonionic antimicrobials such as triclosan described in U.S. 4,894,220, January 16, 1990 to Nabi et al. Both patents are inco ⁇ orated herein by reference.
  • alkali metal bicarbonate such as sodium bicarbonate.
  • alkali metal bicarbonate such as sodium bicarbonate.
  • compositions of the subject invention are controlled-release drug delivery systems for placement in the periodontal pocket.
  • Such systems include, but are not limited to, the cellulose hollow fibers disclosed in U.S. Pat. No. 4,175,326, issued to Goodson on Nov. 27, 1979; the ethylcellulose films disclosed in U.S. Pat. No. 4,568,535 issued to Loesche on Feb. 4, 1986; the absorbable putty-like material disclosed in U.S. Pat. No. 4,568,536 issued to Kronenthal, Maftei and Levy on Feb. 4, 1986; the biodegradable microspheres and matrix disclosed in U.S. Pat. No. 4,685,883 issued to Jernberg on Aug.
  • Such controlled-release delivery systems generally include a solid matrix, usually of polymeric material, loaded with one or more active agents, the matrix entrapping stannous gluconate. Typically, the active agents diffuse from the solid material into the periodontal pocket over time.
  • Preferred controlled-release drug delivery systems comprise from about 0.001% to about 50%, more preferably from about 0.01% to about 25%, more preferably still from about 0.1% to about 15%, still more preferably from about 1% to about 10%, of stannous gluconate and a controlled-release carrier.
  • the pH of the present compositions and/or its pH in the mouth can be any pH which is safe for the mouth's hard and soft tissues.
  • Such pH*s are generally from about 3 to about 10, preferably from about 5 to about 9.
  • the carrier compositions of the present invention can be made using methods which are common in the oral products area.
  • toothpaste compositions may be prepared by mixing part of the humectant and water together and heating to 66°-71°C.
  • the fluoride source if present, is then added along with the sweetener, the opacifier and the flavor.
  • the present invention in its method aspect involves applying to the gingival and/or oral mucosal tissue safe and effective amounts of the compositions. Generally an amount of at least about 5 grams of a mouthwash and at least about 0.5 of a toothpaste or liquid dentifrice.
  • a preferred method of the subject invention involves the contact of a composition of the subject invention with oral cavity soft tissue for at least about 15 seconds, preferably from about 20 seconds to about 10 minutes, more preferably from about 30 seconds to about 60 seconds.
  • the method often involves expectoration of most of the composition following such contact, preferably followed by rinsing, e.g., with water.
  • the frequency of such contact is preferably from about once per week to about five times per day, more preferably from about thrice per week to about four times per day, more preferably still from about once per day to about thrice per day.
  • the period of such treatment typically ranges from about one day to a lifetime.
  • people may recognize that they will be exposed to a cold's virus and they then can use the products described herein either prior to the exposure, following exposure, or at the first signs of a cold.
  • compositions used in the present method may also be used by the subject as a gargle. Additionally, subjects taking significant doses of Vitamin C may achieve an enhanced colds benefit through the use of the compositions described herein.
  • Titanium Dioxide 0.525 0.525

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Cosmetics (AREA)

Abstract

Compositions à administration orale contenant du gluconate stanneux, offrant une protection contre les refroidissements et la grippe.
PCT/US1997/018508 1996-10-22 1997-10-14 Compositions a administration orale contenant du gluconate stanneux WO1998017237A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
BR9712993-3A BR9712993A (pt) 1996-10-22 1997-10-14 Composições orais contendo gluconato estanoso.
CA002269473A CA2269473A1 (fr) 1996-10-22 1997-10-14 Compositions a administration orale contenant du gluconate stanneux
EP97911712A EP0939612A1 (fr) 1996-10-22 1997-10-14 Compositions a administration orale contenant du gluconate stanneux
AU49021/97A AU722452B2 (en) 1996-10-22 1997-10-14 Oral compositions containing stannous gluconate

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73529096A 1996-10-22 1996-10-22
US08/735,290 1996-10-22

Publications (1)

Publication Number Publication Date
WO1998017237A1 true WO1998017237A1 (fr) 1998-04-30

Family

ID=24955163

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/018508 WO1998017237A1 (fr) 1996-10-22 1997-10-14 Compositions a administration orale contenant du gluconate stanneux

Country Status (7)

Country Link
EP (1) EP0939612A1 (fr)
KR (1) KR20000052736A (fr)
CN (1) CN1238673A (fr)
AU (1) AU722452B2 (fr)
BR (1) BR9712993A (fr)
CA (1) CA2269473A1 (fr)
WO (1) WO1998017237A1 (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6294186B1 (en) 1997-06-04 2001-09-25 Peter William Beerse Antimicrobial compositions comprising a benzoic acid analog and a metal salt
US6303104B1 (en) * 1999-02-12 2001-10-16 Enamelon, Inc. Remineralizing/mineralizing oral products having improved whitening and stain removal properties
US6416981B1 (en) 2000-05-23 2002-07-09 Nec Partnership Production of gluconate salts
US6436885B2 (en) 2000-01-20 2002-08-20 The Procter & Gamble Company Antimicrobial cleansing compositions containing 2-pyrrolidone-5-carboxylic acid
US6846478B1 (en) 1998-02-27 2005-01-25 The Procter & Gamble Company Promoting whole body health
US8277782B2 (en) 2000-06-30 2012-10-02 The Procter & Gamble Company Topical oral care compositions comprising host response modulating agents
EP3871693A1 (fr) * 2005-09-27 2021-09-01 Special Water Patents B.V. Compositions pour l'hygiène buccale
EP3157498B1 (fr) * 2014-06-18 2023-06-07 Meda OTC AB Composition pour la prévention ou le traitement de l'érosion dentaire

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030045530A (ko) * 2001-12-04 2003-06-11 김명중 금박 치약 조성물 및 그 제조방법
CN104930773B (zh) * 2015-07-06 2017-06-06 珠海格力电器股份有限公司 电子膨胀阀的控制方法及装置和空调器
MX387471B (es) * 2015-12-30 2025-03-18 Colgate Palmolive Co Producto para el cuidado bucal y métodos para uso y fabricación de este.

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB779504A (en) * 1954-03-11 1957-07-24 American Cyanamid Co Tetracycline antibiotic complexes
EP0311260A2 (fr) * 1987-09-14 1989-04-12 The Procter & Gamble Company Composition buccales
EP0311259A2 (fr) * 1987-09-14 1989-04-12 The Procter & Gamble Company Compositions buccales
US5004597A (en) * 1987-09-14 1991-04-02 The Procter & Gamble Company Oral compositions comprising stannous flouride and stannous gluconate
WO1993007850A1 (fr) * 1991-10-23 1993-04-29 The Procter & Gamble Company Procedes de reduction de la plaque dentaire et de la gingivite avec une coloration reduite
WO1993007852A1 (fr) * 1991-10-23 1993-04-29 The Procter & Gamble Company Procedes de reduction de la plaque dentaire et de la gingivite avec une coloration reduite
US5281411A (en) * 1992-07-31 1994-01-25 The Procter & Gamble Company Oral compositions
US5338537A (en) * 1993-10-05 1994-08-16 The Procter & Gamble Company Oral compositions

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB779504A (en) * 1954-03-11 1957-07-24 American Cyanamid Co Tetracycline antibiotic complexes
EP0311260A2 (fr) * 1987-09-14 1989-04-12 The Procter & Gamble Company Composition buccales
EP0311259A2 (fr) * 1987-09-14 1989-04-12 The Procter & Gamble Company Compositions buccales
US5004597A (en) * 1987-09-14 1991-04-02 The Procter & Gamble Company Oral compositions comprising stannous flouride and stannous gluconate
WO1993007850A1 (fr) * 1991-10-23 1993-04-29 The Procter & Gamble Company Procedes de reduction de la plaque dentaire et de la gingivite avec une coloration reduite
WO1993007852A1 (fr) * 1991-10-23 1993-04-29 The Procter & Gamble Company Procedes de reduction de la plaque dentaire et de la gingivite avec une coloration reduite
US5281411A (en) * 1992-07-31 1994-01-25 The Procter & Gamble Company Oral compositions
US5338537A (en) * 1993-10-05 1994-08-16 The Procter & Gamble Company Oral compositions

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6294186B1 (en) 1997-06-04 2001-09-25 Peter William Beerse Antimicrobial compositions comprising a benzoic acid analog and a metal salt
US6846478B1 (en) 1998-02-27 2005-01-25 The Procter & Gamble Company Promoting whole body health
US6303104B1 (en) * 1999-02-12 2001-10-16 Enamelon, Inc. Remineralizing/mineralizing oral products having improved whitening and stain removal properties
US6436885B2 (en) 2000-01-20 2002-08-20 The Procter & Gamble Company Antimicrobial cleansing compositions containing 2-pyrrolidone-5-carboxylic acid
US6416981B1 (en) 2000-05-23 2002-07-09 Nec Partnership Production of gluconate salts
US6828130B2 (en) 2000-05-23 2004-12-07 Nec Partnership Production of gluconate salts
US7267970B2 (en) 2000-05-23 2007-09-11 Nec Partnership Production of gluconate salts
US8277782B2 (en) 2000-06-30 2012-10-02 The Procter & Gamble Company Topical oral care compositions comprising host response modulating agents
EP3871693A1 (fr) * 2005-09-27 2021-09-01 Special Water Patents B.V. Compositions pour l'hygiène buccale
EP3157498B1 (fr) * 2014-06-18 2023-06-07 Meda OTC AB Composition pour la prévention ou le traitement de l'érosion dentaire

Also Published As

Publication number Publication date
CN1238673A (zh) 1999-12-15
CA2269473A1 (fr) 1998-04-30
EP0939612A1 (fr) 1999-09-08
AU4902197A (en) 1998-05-15
AU722452B2 (en) 2000-08-03
BR9712993A (pt) 2000-04-18
KR20000052736A (ko) 2000-08-25

Similar Documents

Publication Publication Date Title
US6235269B1 (en) Oral care compositions comprising chlorite and methods
US6077502A (en) Oral care compositions comprising chlorite and methods
EP0344701B1 (fr) Compositions orales
EP0652743B1 (fr) Compositions orales
US6251372B1 (en) Oral care compositions comprising chlorite and methods
RU2455001C2 (ru) Композиции и способы лечения ксеростомии
US5389360A (en) Oral compositions
AU722452B2 (en) Oral compositions containing stannous gluconate
JPH02286613A (ja) 新規組成物
EP0311260A2 (fr) Composition buccales
WO1998017270A1 (fr) Compositions orales contenant des sels de citrate de zinc
US5496539A (en) Oral compositions
EP0954294A1 (fr) Utilisation d'antagonistes de h2 pour preparer une composition topique pour le traitement des rhumes
EP0311259A2 (fr) Compositions buccales
MXPA99003767A (en) Oral compositions containing zinc citrate salts
MXPA99003764A (en) Oral compositions containing stannous gluconate

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 97180028.6

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AU BR CA CN KR MX SG

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2269473

Country of ref document: CA

Ref document number: 2269473

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/1999/003764

Country of ref document: MX

Ref document number: 1019997003536

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 1997911712

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1997911712

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1019997003536

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1997911712

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: 1019997003536

Country of ref document: KR

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载